Could a chemo drug tame a rare immune disorder?
NCT ID NCT07555405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug decitabine in 6 boys with XMEN disease, a rare genetic condition that weakens the immune system and damages the liver. The goal is to see if decitabine can improve liver function and immune cell activity. It is a very early, small trial focused on safety and signs of benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Decitabine (a chemotherapy drug given by IV)
- What this could lead to
- If it works, this could point toward a treatment for XMEN disease, a rare immune disorder that makes patients prone to severe infections and liver problems.
- What could go wrong
- This is a very small, early trial with only 6 participants, so results may not apply to everyone. Decitabine is a chemotherapy drug and can cause serious side effects like low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAGT1 DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, 201102, China